EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Integrative proteomics reveals MSH6 to modulate PARP inhibitor sensitivity in BRCA1/2-proficient ovarian cancer

Ou Deng iD, Thales Da Costa Nepomuceno, Bin Fang, Eric A Welsh, Victoria Izumi, Rachael H Martin, Erin M George, John M Koomen iD, Alvaro N Monteiro, Uwe Rix

PLOS One · 2026

DOI: 10.1371/journal.pone.0357365 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2026. Verfasst von Ou Deng und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Drug Discovery, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States of America. Hauptthemen laut MEDLINE: Poly(ADP-ribose) Polymerase Inhibitors, Ovarian Neoplasms, Proteomics, BRCA2 Protein. Die Arbeit nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Hearing the Ovarian Cancer Whisper Jacquie Liggett Fellowship, Sarasota foundation fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ovarian cancer remains a leading cause of gynecologic cancer–related deaths worldwide. Deficiencies in BRCA1/2 are well-established biomarkers that predict sensitivity to poly(ADP-ribose) polymerase inhibitors (PARPis). However, emerging evidence indicates that a subset of BRCA -proficient tumors also responds to PARPi therapy, suggesting the presence of additional molecular mechanisms. We hypothesized that the composition of the PARP1 protein complex and PARylation-mediated signaling contribute to PARPi response in BRCA -proficient HGSOC. We assessed PARPi response across a panel of BRCA -proficient ovarian cancer cell lines and identified distinct sensitive and resistant groups. Chemical proteomics with rucaparib revealed different PARP1 complexes including higher enrichment of MSH6 in sensitive cells. Co-immunoprecipitation analyses further confirmed differential assembly of PARP1–MSH6–PARP2 complexes between sensitive and resistant models. To explore PARylation signaling, we performed ADP-ribosylation proteomics using clickable NAD⁺ analogs, revealing distinct PARylation profiles between sensitive and resistant cell lines. CHAF1A, a known MSH6 interactor and PARP1 substrate, showed more pronounced reduction in ADP-ribosylation in PARPi-sensitive cells. Targeting MSH6 using CRISPR or siRNA decreased PARPi sensitivity. In addition, mTOR signaling was reduced in sensitive, but increased in resistant cells, following rucaparib treatment. Notably, MSH6 knockdown led to increased CHAF1A expression regardless of rucaparib treatment. Importantly, knockdown of CHAF1A significantly impaired cell viability, especially in A2780 cells, and suppressed mTOR signaling, suggesting that CHAF1A acts downstream of MSH6 to regulate the mTOR axis. Furthermore, co-treatment with mTORC1 inhibitors enhanced the cellular effects of rucaparib in resistant cells, suggesting a therapeutic potential of targeting downstream mTOR effectors to overcome intrinsic resistance. In conclusion, this study identifies the PARP1–MSH6 interaction to modulate PARPi sensitivity via CHAF1A-mTOR signaling in BRCA -proficient ovarian cancer. By integrating chemical proteomics and ADP-ribosylation proteomics, we delineate the interplay between PARP1 complex composition and signaling dynamics, highlighting MSH6 as a critical modulator of PARPi response and potential biomarker to enhance therapeutic efficacy in BRCA -proficient HGSOC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Poly(ADP-ribose) Polymerase InhibitorsOvarian NeoplasmsProteomicsBRCA2 ProteinBRCA1 ProteinDNA-Binding ProteinsHumansFemaleCell Line, TumorPoly (ADP-Ribose) Polymerase-1Drug Resistance, NeoplasmSignal TransductionIndolesTOR Serine-Threonine Kinases

Substanzen

Poly(ADP-ribose) Polymerase InhibitorsPoly (ADP-Ribose) Polymerase-1BRCA2 ProteinBRCA1 ProteinDNA-Binding ProteinsPARP1 protein, humanrucaparibIndolesTOR Serine-Threonine KinasesBRCA1 protein, human

Autor:innen und Institutionen

  • Department of Drug Discovery, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States of America.
  • Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States of America.
  • Proteomics & Metabolomics Core, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States of America.
  • Biostatistics and Bioinformatics Shared Resource, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States of America.
  • Department of Gynecologic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States of America.
  • Molecular Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States of America.

ORCID-Profile: Ou Deng, John M Koomen

Förderung

  • NCI NIH HHS
  • Hearing the Ovarian Cancer Whisper Jacquie Liggett Fellowship
  • Sarasota foundation fund
  • National Institutes of Health, National Cancer Institute
  • National Cancer Institute

Zitieren

APA

Deng, O., Nepomuceno, T. D. C., Fang, B., Welsh, E. A., Izumi, V., Martin, R. H., George, E. M., Koomen, J. M., Monteiro, A. N., & Rix, U. (2026). Integrative proteomics reveals MSH6 to modulate PARP inhibitor sensitivity in BRCA1/2-proficient ovarian cancer. PLOS One. https://doi.org/10.1371/journal.pone.0357365

Vancouver

Deng O, Nepomuceno TDC, Fang B, Welsh EA, Izumi V, Martin RH, et al. Integrative proteomics reveals MSH6 to modulate PARP inhibitor sensitivity in BRCA1/2-proficient ovarian cancer. PLOS One. 2026. doi:10.1371/journal.pone.0357365

BibTeX
@article{Deng2026,
  author = {Deng, Ou and Nepomuceno, Thales Da Costa and Fang, Bin and Welsh, Eric A and Izumi, Victoria and Martin, Rachael H and George, Erin M and Koomen, John M and Monteiro, Alvaro N and Rix, Uwe},
  title = {Integrative proteomics reveals MSH6 to modulate PARP inhibitor sensitivity in BRCA1/2-proficient ovarian cancer},
  journal = {PLOS One},
  year = {2026},
  doi = {10.1371/journal.pone.0357365}
}
Kostenlos starten →